Maximilian Marhold

11PUBLICATIONS
36CO-AUTHORS
Haematological tumoursPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsOncology and carcinogenesis not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jun 26, 2026
Characterization of HER2 Expression Levels, Including HER2-Ultralow, in a Retrospective Male Breast Cancer Cohort.

|Aug 05, 2025
HER2/CEP17 ratio predicts residual cancer burden after neoadjuvant dual HER2 blockade: real-world data in patients with primary HER2-amplified breast cancer.

Myriam Stolz, Alex Farr, Kristina A Tendl-Schulz

|May 30, 2025
Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial.

Matthias Preusser, Javier Garde-Noguera, Juan José García-Mosquera

|Jan 17, 2025
Neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in women with early HER2-positive breast cancer: the randomized phase 2 ABCSG-52/ATHENE trial.

Gabriel Rinnerthaler, Daniel Egle, Rupert Bartsch

|Feb 25, 2023
Comparison of RNA Marker Panels for Circulating Tumor Cells and Evaluation of Their Prognostic Relevance in Breast Cancer.

Eva Welsch, Eva Schuster, Michael Krainer

|Nov 26, 2022
Current Developments in Cellular Therapy for Castration Resistant Prostate Cancer: A Systematic Review of Clinical Studies.

Christina Steinbach, Almas Merchant, Alexandru-Teodor Zaharie

Pageof 2

Frequent Collaborators

4 joint publications

Michael Krainer

2 joint publications

Anna Sophie Berghoff

2 joint publications

Matthias Preusser

2 joint publications

Rupert Bartsch